This short review focuses on the role of hematopoietic SCT (HSCT) in childhood AML. In first CR (CR1), some studies demonstrate superiority of allogeneic HSCT with HLA identical sibling donors over the continuation of chemotherapy and others did not. The studies differ in regard to the included risk categories of patients and the outcome niveau of the chemotherapy arm. The BFM98 study found no benefit in having a donor, in particular in terms of overall survival. Autologous HSCT in CR1 is not superior in any of the reviewed trials over the continuation of chemotherapy. In second CR, evidence for the function of allogeneic HSCT is small. However, published data and evidence-based reports recommend an unrelated or related transplantation in the situation of a renewed remission. Data on haploidentical HSCT and on cord blood HSCT are still lacking in the case of AML. Combined studies of larger study groups are warranted to broaden the data basis for rational decision.
Introduction
Chemotherapy and autologous and allogeneic hematopoietic SCT (HSCT) are established methods in the treatment of AML in children. However, it is uncertain whether to use HSCT in first CR (CR1), in second CR (CR2) or in refractory state. It has also been discussed, whether to include all risk groups or high risk (HR) only and how to define risk groups at all. A point of discussion is the exclusive use of matched sibling donors only or also the inclusion of matched unrelated donors or even haploidentical family donors in the treatment of CR1 patients. This short review will focus on the question of remission state and the available donors. For more details there are excellent overviews such as the recently published systematic review of the American Society of Blood and Marrow Transplantation. 1 It is a challenge for the responsible physician to select for each patient the best post-remission treatment applicable in the particular patient's situation.
Allogeneic HSCT in CR1
Most studies performed in this area included post-remission chemotherapy, allogeneic and autologous HSCT in their treatment schedule.
Ortega et al. 2 treated in his study AML88, from April 1988 to May 2001, 79 children from which 50 ( ¼ 63%) fulfilled HR criteria. The conditioning was done with CY plus TBI (except for children younger than 3 years of age (BU plus etoposide). From the HR patients 48 achieved CR or PR. Of these, 17 patients received allogeneic HSCT and 31 received autologous HSCT. TRM rate was 5.9%, and relapse rate was 17.6% in allogeneic HSCT and 3.2 and 25.8% in autologous HSCT. EFS at 8 years resulted in 74.5% in allogeneic HSCT and 74.2% in autologous HSCT.
In the CCG 2891 study, 3 181 from 537 were treated after remission by allogeneic HSCT and 177 by autologous HSCT. Survival and disease-free survival (DFS) in allogeneic HSCT were superior to autologous HSCT and to continuation of chemotherapy; the 8-year DFS was 55% for patients with allogeneic HSCT, 42% for patients randomized to autologous HSCT and 47% for patients who continued chemotherapy. The difference was significantly superior (P ¼ 0.01) when comparing allogeneic HSCT and chemotherapy. The 8-year overall survival was 60, 48 and 53%, respectively, with a P ¼ 0.05 (allogeneic HSCT vs chemotherapy). In this study, patients of all risk groups have been included.
In contrast, in the MRC10 trial 4 no significant difference in the donor vs no donor comparison could be detected: patients with donor (n ¼ 85) had cumulatively 39% events (4% death in CR1, 9% death after BMT, 26% relapses) as compared with 50% in 230 patients without donor (6, 1 and 42%, respectively). Seven-year overall survival was 70% for the donor and 60% for the no-donor group (P ¼ 0.10).
In a systematic review and meta-analysis, 5 6 trials with donor vs no donor comparisons were analysed. The overall result of meta-analysis showed an advantage for matched sibling transplantation in a total of 1486 analysed patients.
In the donor group, there were 161 events (relapse or death), whereas in the no-donor group 615 of 1080 patients had an event. In contrast to the overall results, only two single studies showed a benefit (CCG 2891 and LAME 98/91), whereas the others (AEIOP, CCG 213, MRC AML 10 and RAHC) did not demonstrate any advantage. The drawback of CCG 2891 is the inclusion of all patients, also those with good risk parameters. Another meta-analysis, 6 which also includes CCG 2891, reviews the outcome of 1464 children less than 21 years old at diagnosis in five consecutive Children's Cancer Group acute myeloid leukemia trials between 1979 and 1996. A BMT was performed in 373 children in CR1 in which a matched sibling donor was available. The remaining children were assigned to consolidation chemotherapy (n ¼ 688) or autologous purged BMT (n ¼ 217), or withdrew from study before assignment, or with unknown data (n ¼ 186). Overall and DFS at 8 years were superior for children assigned to allogeneic transplants (allogeneic HSCT vs autologous HSCT vs chemotherapy: DFS 47 vs 42 vs 34% P ¼ 0.004; overall survival: 54 vs 49 vs 42% P ¼ 0.06). In this study also included were children with good risk cytogenetics.
The BFM-AML 98 trial compared in a genetic randomization patients in CR1 with available matched sibling donors in an intention to treat analysis with patients without donor. 7 From 317 HR patients, 275 (86.7%) achieved a CR. Of 275 patients, 58 (21.1%) had an HLA identical sibling donor. Intention to treat analysis revealed no difference in DFS at 5 years (donor vs no donor, 0.47 vs 0.41, P ¼ 0.40). In addition survival at 5 years was not different (donor vs no donor, 0.55 vs 0.54, P ¼ 0.16). The recently published results of the CCG-2961 trial incorporated three new agents (idarubicin, fludarabine and IL-2) into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor BMT or highdose cytarabine intensification. 8 Among 901 patients under the age of 21 years, 5-year survival was 52% and EFS was 42%. For patients with or without a related donor, the 5-year DFS was 61 and 50%, respectively (P ¼ 0.021); survival was 68 and 62%, respectively (P ¼ 0.425). In this study, patients of all risk categories were included. Table 1 summarizes the key data of these studies.
In contrast, BFM studies show that patients with goodrisk leukemia defined by cytogenetics (t(8;21), inv16, t(15;17)) are no candidates for allogeneic transplantation; this is supported by other authors also.
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Autologous HSCT in CR1 Data on autologous transplantation in CR1 are included in the publications from Alonzo et al., 6 Ortega et al., 2 Woods et al. 3 and Stevens et al. 4 There is no superiority of autologous HSCT over continuation of chemotherapy in any of the reported trials.
Allogeneic HSCT in CR2
For CR2 there is only scant existing evidence. Wells et al.
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presented data from 101 patients treated with refractory (16%) or relapsed (84%) AML within the CCG 2951 trial. Thirteen patients received further chemotherapy after induction, and 35 patients underwent HSCT (30 matched unrelated donors, 4 related donors and 1 from unknown donors). The 2-year DFS and survival were not significantly different in both groups. 
Haploidentical HSCT in childhood AML
In spite of excellent data for haploHSCT in adults, 12 there is less evidence for the role of haploHSCT in AML in CR1, CR2 or refractory state. Most authors reporting haploHSCT in children include a small series in larger retrospective reports for acute leukemia or malignant diseases. 13 
Cord blood transplantation
In a Eurocord analysis, the use of unrelated cord blood was analysed for the treatment of AML.
14 Ninety-five children receiving unrelated cord blood transplantation for AML (20 in CR1, 47 in CR2 and 28 in more advanced stage) were found. Poor prognosis cytogenetic abnormalities were identified in 29 cases. Most patients received a one or two HLA Ag mismatched unrelated cord blood transplantation. The 2-year cumulative incidence of relapse was 29% and was associated with disease status. The 2-year leukemia free survival (LFS) was 42% (59% in CR1, 50% in CR2 and 21% for children not in CR).
Conclusions
For CR1, according to the available evidence, only HR patients should be included in HSCT strategies. There are studies demonstrating the superiority of allogeneic matched sibling donors HSCT in CR1 over continuation of chemotherapy 3, 6, 8 and other studies that could find no difference. 4, 7 It is also remarkable that the study of Alonzo et al. 6 could not find a benefit for survival in spite of finding an advantage for DFS. That agrees with our data, 7 which demonstrate that patients having a donor have an advantage over those who do not if they are transplanted by HSCT in CR1. However, survival at 5 years is identical because those relapsing can be rescued if transplanted at that time. The identical overall survival reduces the necessity for transplantation procedures if using the donor only for the rescue strategy.
For CR2, there is little published evidence. However, most experts in this field would prefer as post-remission treatment allogeneic HSCT in particular in early (o1 year after diagnosis) relapse. 1 For evaluating the role of haploHSCT and of unrelated cord blood as stem cell source for the treatment of AML, too few data are available. For the future, controlled studies in this field are needed.
However, the role of HSCT in CR1 of AML treatment has to be defined by each study group taking into consideration the outcome levels of chemotherapy. 15 No general answer is possible at the moment.
